HK Stock Market Move | HENLIUS (02696) rose more than 13% in early trading. H Medicine has been approved for a new indication in the European Union, achieving full coverage of first-line treatment for core subtypes of lung cancer.

HENLIUS (02696) surged more than 13% in early trading, as of the time of writing, it was up 13.33% at 62.9 Hong Kong dollars, with a trading volume of 34.7527 million Hong Kong dollars. On the news front, on June 25th, HENLIUS announced that its independently developed anti-PD-1 monoclonal antibody drug Hansilu (Sulirumab monoclonal antibody) has been approved by the European Commission for use in combination with chemotherapy for first-line treatment of inoperable locally advanced or metastatic squamous non-small cell lung cancer in adult patients. This is the fourth indication approved for Hansilu in the European Union, marking its broad coverage in the EU market for first-line treatment of core subtypes of lung cancer. As the core product of HENLIUS' global strategy, Hansilu is currently approved for marketing in 50 countries and regions worldwide. The company is continuously advancing international clinical research and registration applications for the drug focusing on high-incidence cancers such as lung cancer and gastrointestinal tumors. It is also simultaneously promoting bridging research and registration plans in markets such as the United States and Japan to strengthen its global commercialization foundation.